Interim Report – January to September 2019

Dokument -

Interim Report – January to September 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter of 2019.
  • Licens: All rights reserved
    Innehållet får bara användas av Mynewsdesk. Det är alltså inte tillåtet för någon annan att ladda ner, kopiera, sprida eller på annat sätt använda Innehållet (annat än för privat bruk i den mån det följer av lag).
  • Filformat: .pdf

Kontakter

David Bejker

Presskontakt CEO

Relaterat innehåll

Interim Report – January to September 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter of 2019.